GSK Licenses Ex-China Rights to HUTCHMED’s KRAS-EGFR Conjugate
HUTCHMED granted a GSK subsidiary exclusive rights outside Greater China to HMPL-A830, a preclinical antibody-targeted therapy conjugate that links an anti-EGFR antibody with a KRAS-inhibitor payload. HUTCHMED is eligible for $110 million upfront at…
